Low immunohistochemical staining expression of INPP5A predicts poor overall survival in recurrent and metastatic cutaneous squamous cell carcinoma.
Long-term results show that thicker melanomas (>2 mm) can safely be excised with a 2-cm margin.
A meta-analysis sought to determine if survival is improved with dual targeting of the MAPK pathway with BRAF and MEK inhibitors vs BRAF inhibition alone in patients with advanced melanoma.
In a general—not patient—population, a “remarkable” number of lesions could not be analyzed by the most popular smartphone mole evaluation app.
From 2001 to 2016, the use of Mohs surgery for melanoma increased more than threefold.
A melanoma risk prediction model may assist clinicians in stratifying patients by melanoma risk for targeted preventive interventions.
Dabrafenib and trametinib combination therapy shows success in 5-year survival in one-third of patients with unresectable or metastatic melanoma and a BRAF V600E or V600K mutation.
Study data found that ingenol mebutate 0.027% was superior to vehicle as a short-term field treatment for patients with actinic keratosis.
Less than half of health care providers discuss sun-safe behaviors with patients.
The reported number-needed-to-biopsy for cutaneous melanoma varies widely across clinicians, geography, and patient populations, underscoring the need for uniformity in the metric.